Reaction Details Report a problem with these data
Target
cGMP-specific 3',5'-cyclic phosphodiesterase
Ligand
BDBM50036632
Substrate
n/a
Meas. Tech.
ChEMBL_1433727 (CHEMBL3386398)
IC50
1.8±n/a nM
Citation
 Sakamoto, T; Koga, Y; Hikota, M; Matsuki, K; Murakami, M; Kikkawa, K; Fujishige, K; Kotera, J; Omori, K; Morimoto, H; Yamada, K The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor. Bioorg Med Chem Lett 24:5460-5 (2015) [PubMed]  Article 
Target
Name:
cGMP-specific 3',5'-cyclic phosphodiesterase
Synonyms:
CGB-PDE | PDE5 | PDE5A | PDE5A_CANLF | Phosphodiesterase 5A | cGMP-binding cGMP-specific phosphodiesterase | cGMP-specific 3',5'-cyclic phosphodiesterase
Type:
PROTEIN
Mol. Mass.:
98285.03
Organism:
Canis lupus familiaris
Description:
ChEMBL_105565
Residue:
865
Sequence:
MERGSPGAGAARLPRDQDSVEAWLDDHRDFTFSYFVKKATREMVNAWFAERVHTIPVCKEGIRGHAESCSCSSQQSSRADSSAPGTPTRKISASEFDRPLRPIVVKDSEGTVSFLADSEKKEQMPLTPPRFDNDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLISADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEASNNCIRLEWNKGIVGHVAALGEPLNIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDEKDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIISFMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKLPDTLTRERDANRINYMYAQYVKNTMEPLNIPDVSKDKRFPWTNENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGKVKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETKELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGVNNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPADLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAEQQEKTLINGESSQAKRN
  
Inhibitor
Name:
BDBM50036632
Synonyms:
CHEMBL3354284
Type:
Small organic molecule
Emp. Form.:
C24H32ClN5O4
Mol. Mass.:
489.995
SMILES:
COc1ccc(CNc2nc(ncc2C(=O)N[C@H]2CC[C@H](O)CC2)N2CCC[C@H]2CO)cc1Cl |r,wU:17.17,28.31,wD:20.21,(27.61,-1.23,;26.27,-.47,;24.94,-1.24,;23.59,-.48,;22.27,-1.26,;22.29,-2.79,;20.96,-3.57,;20.97,-5.11,;19.64,-5.89,;18.3,-5.12,;16.98,-5.9,;16.98,-7.44,;18.31,-8.21,;19.64,-7.43,;20.98,-8.2,;22.31,-7.43,;20.98,-9.74,;22.32,-10.51,;23.64,-9.73,;24.98,-10.51,;24.98,-12.05,;26.31,-12.82,;23.64,-12.82,;22.31,-12.05,;15.65,-5.13,;14.23,-5.76,;13.2,-4.62,;13.97,-3.28,;15.48,-3.6,;16.61,-2.57,;18.08,-3.03,;23.62,-3.56,;24.95,-2.79,;26.28,-3.55,)|
Structure:
Search PDB for entries with ligand similarity: